Ardelyx, Inc. (ARDX) stock
ARDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3058% below fair value
$3.12−0.06 (-1.89%)
Close on Nov 18, 2026Market cap $777.46MP/E –Yield –
Ardelyx operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Ardelyx's operating income for the twelve months ending Jun 30, 2026 was -$35.45M. For fiscal 2025 it was -$40.98M. The highest annual figure on record is -$1.56M in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$40.98M | – |
| FY2024 | Dec 31, 2024 | -$27.95M | – |
| FY2023 | Dec 31, 2023 | -$63.28M | – |
| FY2022 | Dec 31, 2022 | -$63.76M | – |
| FY2021 | Dec 31, 2021 | -$154.35M | – |
| FY2020 | Dec 31, 2020 | -$90.78M | – |
| FY2019 | Dec 31, 2019 | -$91.26M | – |
| FY2018 | Dec 31, 2018 | -$90.95M | – |
| FY2017 | Dec 31, 2017 | -$65.12M | – |
| FY2016 | Dec 31, 2016 | -$112.90M | – |
| FY2015 | Dec 31, 2015 | -$29.39M | – |
| FY2014 | Dec 31, 2014 | -$1.56M | – |
| FY2013 | Dec 31, 2013 | -$2.87M | – |
| FY2012 | Dec 31, 2012 | -$8.81M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$12.43M | – |
| Q1 FY2026 | Mar 31, 2026 | -$32.79M | – |
| Q4 FY2025 | Dec 31, 2025 | $5.10M | -37.2% |
| Q3 FY2025 | Sep 30, 2025 | $4.67M | +109.0% |
| Q2 FY2025 | Jun 30, 2025 | -$14.40M | – |
| Q1 FY2025 | Mar 31, 2025 | -$36.35M | – |
| Q4 FY2024 | Dec 31, 2024 | $8.13M | – |
| Q3 FY2024 | Sep 30, 2024 | $2.23M | -69.8% |
| Q2 FY2024 | Jun 30, 2024 | -$13.63M | – |
| Q1 FY2024 | Mar 31, 2024 | -$24.68M | – |
| Q4 FY2023 | Dec 31, 2023 | -$27.99M | -330.5% |
| Q3 FY2023 | Sep 30, 2023 | $7.40M | – |
| Q2 FY2023 | Jun 30, 2023 | -$16.62M | – |
| Q1 FY2023 | Mar 31, 2023 | -$26.06M | – |
| Q4 FY2022 | Dec 31, 2022 | $12.14M | – |
| Q3 FY2022 | Sep 30, 2022 | -$21.88M | – |
| Q2 FY2022 | Jun 30, 2022 | -$26.22M | – |
| Q1 FY2022 | Mar 31, 2022 | -$27.81M | – |
| Q4 FY2021 | Dec 31, 2021 | -$35.27M | – |
| Q3 FY2021 | Sep 30, 2021 | -$42.24M | – |
| Q2 FY2021 | Jun 30, 2021 | -$44.83M | – |
| Q1 FY2021 | Mar 31, 2021 | -$32.01M | – |
| Q4 FY2020 | Dec 31, 2020 | -$27.64M | – |
| Q3 FY2020 | Sep 30, 2020 | -$17.16M | – |
| Q2 FY2020 | Jun 30, 2020 | -$24.21M | – |
| Q1 FY2020 | Mar 31, 2020 | -$21.77M | – |
| Q4 FY2019 | Dec 31, 2019 | -$18.85M | – |
| Q3 FY2019 | Sep 30, 2019 | -$22.09M | – |
| Q2 FY2019 | Jun 30, 2019 | -$24.83M | – |
| Q1 FY2019 | Mar 31, 2019 | -$25.50M | – |
| Q4 FY2018 | Dec 31, 2018 | -$27.38M | -349.7% |
| Q3 FY2018 | Sep 30, 2018 | -$23.73M | – |
| Q2 FY2018 | Jun 30, 2018 | -$22.15M | – |
| Q1 FY2018 | Mar 31, 2018 | -$17.69M | – |
| Q4 FY2017 | Dec 31, 2017 | $10.96M | – |
| Q3 FY2017 | Sep 30, 2017 | -$21.23M | – |
| Q2 FY2017 | Jun 30, 2017 | -$26.42M | – |
| Q1 FY2017 | Mar 31, 2017 | -$28.43M | – |
| Q4 FY2016 | Dec 31, 2016 | -$31.48M | – |
| Q3 FY2016 | Sep 30, 2016 | -$29.20M | – |
See a number that looks wrong?